The mechanism of human immunodeficiency virus type 1 (HIV-1) cytopathicity is poorly understood and might involve formation of multinucleated giant cells (syncytia), single-cell lysis, or both. In order to determine the contributions of the fusion domain to syncytium formation, single-cell lysis, and viral infectivity and to clarify the molecular details of these events, insertion mutations were made in the portion of env encoding this sequence in the functional HIV-1 proviral clone HXB2. Viruses produced from these mutant clones were found to have a partial (F3) or complete (F6) loss of syncytium-forming ability in acutely infected CEM, Sup Ti, and MT4 T-cell lines. During the early stage of acute infection by F6 virus, there was a loss of the syncytial cytopathic effect, which resulted in increased cell viability, and a 1.9-to 2.6-fold increase in virus yield in the cell lines tested. In the late stage of acute infection, the single-cell cytopathic effect of F6 virus was similar to that of the parental HXB2 virus. The F3 and F6 viruses were also found to have a 1.7-to 43-fold reduction in infectivity compared with the HXB2 virus. The mutant F3 and F6 and parental HXB2 envelope proteins were expressed in vaccinia virus, and the mutant envelope proteins were observed to be defective in their ability to form syncytia. BSC-40 cells infected with vaccinia virus recombinants revealed no differences in kinetics of cleavage, cell surface expression, or CD4 binding capacity of the mutant and parental envelope proteins. These results demonstrate that a loss of syncytium formation results in an attenuation of infectivity and a loss of the syncytial cytopathic effect without a loss of single-cell lysis. These mutants may reflect in tissue culture the changes observed in the HIV isolates in vivo during disease progression, which exhibit marked differences in syncytium production.
Human immunodeficiency virus type 1 (HIV-1) is the etiologic agent of AIDS (3) . The disease is characterized by an initial infection followed by a latency period of up to several years and then by severe depletion of the CD4+ T cells. As a consequence of T-cell depletion and resulting immunodeficiency, patients become susceptible to lifethreatening opportunistic infections. Virus isolates from HIV-positive patients, obtained at the asymptomatic stage of infection to the disease stage of AIDS or AIDS-related complex, have been found to differ in infectivity, tissue tropism, and replication kinetics (7, 31, 36) . Sequential isolates from patients that progressed from asymptomatic infection to AIDS or AIDS-related complex revealed a transition from virus strains that replicated slowly, with only low levels of reverse transcriptase (RT) production (slow/ low viruses), to viruses that replicated rapidly, yielding high levels of RT (rapid/high viruses; 7, 31). Another characteristic feature of virus isolates from the late symptomatic stages but not early asymptomatic infection period of disease was the capacity to induce syncytium formation (7, 31, 35, 36) . Although multinucleated giant cells have been observed in histologic sections from the brains of infected individuals (24, 32) , the precise role of syncytium induction in disease onset in vivo is not known.
The HIV envelope glycoproteins are initially synthesized as a 160-kDa precursor (gpl60), which is subsequently cleaved into a 120-kDa surface protein (gpl20, designated SU), and a 41-kDa transmembrane protein (designated TM * Corresponding author. [23] ). Eighty-five percent of the synthesized gpl60 is degraded in lysosomes, with only cleaved forms of the envelope proteins reaching the cell surface (37) . The SU protein is bound noncovalently to the TM protein on the cell surface and is responsible for virus binding with its CD4 receptor (17) . The envelope protein expressed in the absence of other HIV proteins, by using a recombinant vaccinia virus (VV), also induced syncytium formation in CD4+ lymphoid cell cultures (19) .
The N-terminal domain of the TM protein exhibits substantial homology with the fusion domain of the paramyxovirus envelope, or F protein (14) . The use of site-directed mutagenesis to disrupt the putative SIV-mac and HIV type 1 (HIV-1) fusion domains supports the role of this domain in syncytium formation (4, 6, 13) . In light of the association of syncytium-forming capacity with disease progression, it was of interest to examine the role of syncytium formation in the HIV-1 life cycle. The current study examined mutants with partial or complete loss of syncytium induction activity in tissue culture. Defects in cell-cell fusion resulted in diminished virus-cell fusion, demonstrating similarities in the mechanism of virus infectivity and multinucleated giant cell formation. The decreased infectivity of the mutant viruses also resulted in an altered tropism for different CD4+ cell lines. However, loss of cell-cell fusion had no Plasmids. The parental HIV-1 proviral clone used for mutagenesis was HXB2 (11, 27) . The tat-expressing CV-1 plasmid was provided by S. Arya (National Cancer Institute [1] ).
Mutations were made in HXB2 by cloning the BamHI-toSall fragment into the TZ18 phagemid vector (Bio-Rad) and using oligonucleotide site-directed mutagenesis (18) . The mutations inserted unique restriction sites into the env gene: NaeI for F3, F6, F6B, and F6D, as well as a PstI site for F6 (Fig. 1) . A mutation which inserted a unique XbaI site prior to the envelope gene was made at positions 5791 to 5793. After this mutation was cloned into HXB2, the env gene was isolated by an XbaI and XhoI restriction digest and cloned into plasmid SC11.4 used for recombination with VV (20 (26) .
Recombinant VV were rescued on CV-1 cells and detected by color selection by using the f-galactosidase marker gene (21) and plaque purified, and stocks were grown and titers were determined on BSC-40 cells (20) .
HIV Radioimmunoprecipitation. Cells (3 x 106) were labeled with Tran35S-label (ICN; specific activity, 1,112 Ci/mmol) in cysteine-and methionine-free medium. Immunoprecipitation was carried out as previously described (2) . Antibodies used for radioimmunoprecipitation were from a pool of sera collected from HIV-positive patients and designated MA. All samples were boiled for 2 min prior to loading on the sodium dodecyl sulfate (SDS) polyacrylamide gel for electrophoresis (SDS-PAGE). (4, 13) . In order to examine more subtle conformational effects, the current study examined conservative mutations with insertions of three to six hydrophobic amino acids at the amino terminus of TM (Fig. 1 ). Mutations were confirmed by restriction enzyme analysis and DNA sequence determination (22, 30 (Fig. 3 and data not shown).
Cytopathic effects of the mutant virus preparations were also determined from the number of viable cells after infection of CEM cells (Fig. 2B) . The F3-infected cells demonstrated a slight delay in cell death compared with HXB2-infected cells; this delay correlated with the reduction in syncytium formation activity ( Fig. 2A) Virus production from cells infected with each mutant virus was also analyzed (Fig. 2C) . No significant differences in the kinetics or amount of virus released by F3-and HXB2-infected CEM cells were noted. However, virus production from F6-infected cells was delayed, and the total amount of virus released was 1.9-, 2.3-, and 2.6-fold more than HXB2 in CEM, MT4, and Sup Ti cells, respectively (see legend to Fig. 2 ). In contrast, virus particles were produced from F3-, F6-, and HXB2-transfected Cos-7 cells in equivalent amounts (data not shown).
Syncytium formation assays. Syncytium formation assays were performed with recombinant VV which result in a highly efficient infection at equal levels in the absence of other HIV-1 proteins ( Expression of envelope at the cell surface was examined by iodinating intact VV-infected BSC-40 cells (Fig. 4B) . Equivalent levels of SU and TM proteins were expressed by VV3, VV6, and VVenv. lodination efficiency was examined with gels of nonimmunoprecipitated protein lysates and was found to be equivalent in each case (data not shown). A small amount of iodinated 160-kDa precursor was detected and possibly resulted from a low level of cell disruption in VV-infected cells prior to labeling. However, separation of viable and nonviable cells by centrifugation into a Ficoll gradient, followed by iodination, still resulted in the labeling of some gp160 precursor protein. These results suggest that some gp160 is being expressed on the cell surface. Results of iodination of F3-, F6-, and HXB2-infected Sup Ti cells revealed no precursor envelope on the cell surface, and no reduction of expression of SU on the cell surface was observed with F3 and F6 compared with HXB2 (data not shown).
The ability of the SU protein from the mutant and wildtype envelope proteins to bind to CD4 was also examined using sCD4 bound to OKT4-protein A-Sepharose beads (Fig.  4C) . No differences were observed in the ability of the F3, F6 and parental SU protein to bind to the CD4 receptor. Fifty percent VVenv and 20% VVenv aliquots of labeled infected cell lysates gave rise to bands of comparably reduced intensity, demonstrating that the sCD4 protein was used in vast excess of the levels of SU protein in these assays.
Finally, it has been reported that the HIV-1 envelope protein is assembled into dimers, trimers, and tetramers (10, 25) . Therefore, to determine whether changes in oligomerization may have occurred as a result of these mutations, the mutant and wild-type envelope proteins were sedimented onto a sucrose gradient to separate monomeric envelope from higher-molecular-weight complexes. Immunoprecipitation of envelope proteins found in the different fractions from the gradient revealed no differences in the structure between the mutant (VV6 and VV3) and wild-type (VVenv) envelope proteins (Fig. 5) . The SU protein is found primarily in fractions 8 to 9, consistent with a monomeric form as reported previously (10) . The gp160 precursor is found in fractions 4 to 6, with a sedimentation behavior consistent with that predicted for a dimeric form (10) , and fractions 6 to 8, at which the monomeric form would likely migrate. Lesser amounts of higher-molecular-weight complexes are present in fractions 2 to 4. These complexes have been reported to be trimers and/or tetramers (10) . Similar results were obtained with extracts prepared in nonionic detergents and analyzed by PAGE with only 0.1% SDS (data not shown), conditions previously established for analysis of oligomers of HIV-2 and SIV-mac envelope proteins (28) .
DISCUSSION
The results presented here demonstrate that the fusogenic function of the TM protein may be altered by insertion of hydrophobic amino acids at the amino terminus (Table 2 and Fig. 2 and 3 ). These data suggest that differences in processing, stability, surface expression, receptor binding, and higher-molecular-weight-complex formation are not likely explanations of the loss of fusogenicity observed with the HIV-1 mutants (Fig. 4 and 5 ). These results demonstrate an attenuation of a distinct fusogenic function of the TM protein.
The mechanism by which the fusogenic function is attenuated is not clear but may involve alterations in the angle of insertion of the fusion domain into the lipid bilayer (5). These results are consistent with those of previously reported studies on the fusion domain (4, 13) . Reduction in infectivity (Table 1) , coincident with loss of syncytium formation capacity (Table 2 and Fig. 2 and 3) , allows one to conclude that the fusion domain is important for virus-cell fusion as well. The results presented here for the F6 virus also show that syncytium formation is a more sensitive indicator of proper fusogenic function since fusion can be eliminated while the virus still maintains infectivity. This conclusion is further supported by our work with the glucosidase inhibitor N-butyl deoxynojirimycin. Treatment of infected cells with this agent abolished cell-cell fusion at considerably lower doses than those which affected virus-cell fusion (9) .
The syncytium formation-defective phenotype of the F6 clone has allowed us to define two distinct cytopathic effects of HIV-1 in tissue culture (Fig. 2) . Initially in acute HIV infection, the cytopathic effect associated with syncytium formation is observed. This was demonstrated by the formation of multinucleated cells which were incapable of excluding trypan blue dye, while single cells retained their viability. This effect manifested itself as a marked decline in viable cell number with HXB2-infected cells over a 9-day period. Loss of the syncytial cytopathic effect resulted in a more gradual decline in viable cell number with F6-infected cells over a period of 15 days. Furthermore, the increased viable cell number observed with F6 virus infection resulted in a significant increase in total virus yield. In the absence of syncytia, single-cell lysis was still observed with the F6 virus. This demonstrates that mechanisms other than syncytium formation result in HIV-1-induced cytopathicity.
These findings are in agreement with other studies suggesting two distinct cytopathic mechanisms. Syncytium formation in the absence of the single-cell cytopathic effects may not result in the death of the culture. Fisher and colleagues demonstrated that mutations in the C terminus of TM attenuated single-cell killing but not syncytium formation (12; unpublished observations). Furthermore, cytopathic effects have also been observed in the absence of syncytia in N-butyl deoxynojirimycin-treated, HIV-1-infected cell lines (9) . Other studies have found a poor correlation between the susceptibility of different lymphoid cell lines to HIV-1-mediated cytopathicity and HIV-1-induced syncytium formation (33) . The mechanism by which singlecell lysis occurs is not known but has been suggested to be a function of extremely high levels of viral RNA and protein synthesis (33) or superinfection (34) .
It has recently been reported that syncytium formation is the sole cytopathic mechanism in HIV-1-infected cells (16) . By using an HIV-1 clone that is only partially defective for syncytium formation, reduced cytopathic effects were demonstrated with Jurkat cells and primary lymphocyte cultures. The usefulness of Jurkat cells in this study in determining cytopathicity is not clear, since not all wild-type viruses used in this study demonstrated a substantial cytopathic effect (e.g., the HIV-CAT virus). The data of Kowalski and colleagues with peripheral blood mononuclear cells appears to show significant cytopathic effect, albeit delayed relative to that of the wild-type virus, with the syncytium formationdefective clone (517A). In fact, 517A virus replication kinetics on Jurkat cells show a delay in the peak syncytium formation. This suggests that the 517A virus exhibited a reduction in infectivity, though this parameter was not specifically examined in this study. This may explain the delay in cytopathic effects observed with the 517A virus on peripheral blood mononuclear cells. It is unclear whether the residual cytopathic effects of 517A are due to its residual syncytium induction activity, as suggested by Kowalski and colleagues (16) , or to an alternate pathway of cytopathogenicity, as suggested by the current study.
The results presented in the current study may mimic observations of increasing fusogenicity of sequential viral isolates taken from patients infected with HIV. Thus, on the basis of results presented here, it is possible that naturally occurring virus isolates which induce syncytium formation may have increased infectivity and enhanced cytopathicity. The observed changes in infectivity also resulted in changes in tropism among the T-cell lines tested ( Table 1 ). The loss of infectivity by the F6 virus was not equivalent in all cell lines, varying from complete to partial loss of infectivity. Thus, differences observed in cell tropism in vivo could be the result of an enhancement of infectivity and not of alternative receptors or cell-specific replication properties.
These results have several implications for studies of HIV replication in infected individuals. First, development of therapeutic agents which eliminate virus-induced syncytia may not necessarily eliminate the cytopathic effect of the virus. Second, antibodies designed to neutralize HIV, while eliminating syncytia, will not necessarily eliminate virus entry. Thus assays relying on syncytia as an indication of neutralization of HIV should use additional markers of infection such as p24 antigen production. Third, agents or antibodies that eliminate syncytia could enhance virus production in vivo. Furthermore, it is possible that antibodies that impair syncytium formation could result in increased virus yield (Fig. 2) . This could result in a novel form of antibody-dependent enhancement of virus production, which has not previously been described. Such antibodies which block syncytium formation but do not neutralize virus infectivity have been studied with visna virus infections (8) .
Syncytium formation is probably not the sole determinant of disease progression. Immune selection, enhanced replication properties, and changes in cell tropism are likely to be important as well. The depletion of CD4+ cells may be due to the enhanced cytopathic effects caused by syncytia. An alternate possibility is that enhanced infectivity may accelerate virus spread, followed by single-cell lysis, which may play a more important role than syncytium formation.
